3,410 reports of this reaction
1.9% of all DIAZEPAM ORAL SOLUTION (CONCENTRATE) reports
#8 most reported adverse reaction
SOMNOLENCE is the #8 most commonly reported adverse reaction for DIAZEPAM ORAL SOLUTION (CONCENTRATE), manufactured by Alembic Pharmaceuticals Inc.. There are 3,410 FDA adverse event reports linking DIAZEPAM ORAL SOLUTION (CONCENTRATE) to SOMNOLENCE. This represents approximately 1.9% of all 177,526 adverse event reports for this drug.
Patients taking DIAZEPAM ORAL SOLUTION (CONCENTRATE) who experience somnolence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SOMNOLENCE is a less commonly reported adverse event for DIAZEPAM ORAL SOLUTION (CONCENTRATE), but still significant enough to appear in the safety profile.
In addition to somnolence, the following adverse reactions have been reported for DIAZEPAM ORAL SOLUTION (CONCENTRATE):
The following drugs have also been linked to somnolence in FDA adverse event reports:
SOMNOLENCE has been reported as an adverse event in 3,410 FDA reports for DIAZEPAM ORAL SOLUTION (CONCENTRATE). This does not prove causation, but indicates an association observed in post-market surveillance data.
SOMNOLENCE accounts for approximately 1.9% of all adverse event reports for DIAZEPAM ORAL SOLUTION (CONCENTRATE), making it a notable side effect.
If you experience somnolence while taking DIAZEPAM ORAL SOLUTION (CONCENTRATE), contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.